Promising Direct Acting Antivirals in Cameroon

RESUME But. Lu0027introduction recente du sofosbuvir au Cameroun represente une etape importante dans le traitement des genotypes 1, 2 et 4 de lu0027hepatite C chronique (CHC). Les donnees sur lu0027efficacite de cette association au Cameroun sont rares. Le but de cette etude etait de caracteriser la reponse a lu0027association sofosbuvir ribavirine avec ou sans interferon pegyle au Cameroun. Methodes. Nous avons inclus de maniere consecutive des CHC 1,2 et 4 adultes de deux centres de traitement publics et du0027un centre de traitement prive au Cameroun. Les patients admissibles devaient avoir toutes les reponses virologiques documentees. Les dossiers medicaux des patients qui ont demande un traitement ont ete systematiquement examines par un comite. Lu0027efficacite a ete evaluee par reponse virologique rapide (RVR), reponse de fin de traitement (ETR); et reponse virologique soutenue (RVS). Les evenements indesirables ont ete enregistres. Les donnees ont ete analysees en utilisant le test de Chi-deux de Pearson ou le test exact de Fisher, selon le cas. Resultats: Nous avons inclus 72 patients âges de 31 a 82 ans. Une charge virale elevee etait presente dans 65,2% des cas. Les genotypes 1,2 et 4 representaient respectivement 29,2%, 51,4% et 19,4%. Nous avons eu 33,3% de patients cirrhotiques et 84,7% de patients naifs. 83,3% (60/72) des patients ont atteint la reponse virologique rapide. La reponse en fin de traitement etait presente chez 91,6% (66/72) et la reponse virale soutenue chez 91,6%. Conclusion. ABSTRACT Background: The recent introduction of sofosbuvir in Cameroon represent an important step in the treatment of genotypes 1, 2 and 4 Chronic Hepatitis C (CHC). Data on efficacy of this combination in Cameroon are scarce. The aim of this study was to characterize the response to sofosbuvir ribavirin combination with or without pegylated interferon in Cameroon. Methods: We consecutively included consented CHC 1,2 and 4 adults from two publics and one private treatment centers in Cameroon. Eligible patients were required to have all virological response documented. The medical records of patients who sought treatment were systematically reviewed by a committee. Efficacy was assessed by Rapid Virological Response (RVR), End of Treatment Response (ETR); and Sustained Virological Response (SVR). Adverse events were recorded. Data were analysed using Pearsonu0027s Chi-square test or Fisheru0027s exact test as appropriate. Results: We included 72 patients aged 31 to 82 years. A high viral load was present in 65.2%. Genotypes 1,2 and 4 accounted respectively for 29.2%,51.4% and 19.4%. We had 33.3% cirrhotic and 84.7% naive patients. RVR was achieved by 83.3% (60/72) of patients; ETR by 91.6% (66/72) and SVR by 91.6% (66/72). Conclusion: The formal protocol was pegylated interferon plus ribavirin and we added sofosbuvir. The therapeutic response is by far better than the one without Direct Acting Antiviral (DAA).